318 related articles for article (PubMed ID: 34357961)
1. Huntingtin and Its Role in Mechanisms of RNA-Mediated Toxicity.
Heinz A; Nabariya DK; Krauss S
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357961
[TBL] [Abstract][Full Text] [Related]
2. Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease.
Schilling J; Broemer M; Atanassov I; Duernberger Y; Vorberg I; Dieterich C; Dagane A; Dittmar G; Wanker E; van Roon-Mom W; Winter J; Krauß S
J Mol Biol; 2019 Apr; 431(9):1869-1877. PubMed ID: 30711541
[TBL] [Abstract][Full Text] [Related]
3. Cancer: From Wild-Type to Mutant Huntingtin.
Thion MS; Humbert S
J Huntingtons Dis; 2018; 7(3):201-208. PubMed ID: 29889077
[TBL] [Abstract][Full Text] [Related]
4. The MID1 Protein: A Promising Therapeutic Target in Huntington's Disease.
Heinz A; Schilling J; van Roon-Mom W; Krauß S
Front Genet; 2021; 12():761714. PubMed ID: 34659371
[TBL] [Abstract][Full Text] [Related]
5. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
6. Huntington's Disease Protein Huntingtin Associates with its own mRNA.
Culver BP; DeClercq J; Dolgalev I; Yu MS; Ma B; Heguy A; Tanese N
J Huntingtons Dis; 2016; 5(1):39-51. PubMed ID: 26891106
[TBL] [Abstract][Full Text] [Related]
7. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
8. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
9. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
10. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
11. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
[TBL] [Abstract][Full Text] [Related]
12. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
[TBL] [Abstract][Full Text] [Related]
13. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
[TBL] [Abstract][Full Text] [Related]
14. Huntingtin Lowering Strategies.
Marxreiter F; Stemick J; Kohl Z
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245050
[TBL] [Abstract][Full Text] [Related]
15. RNA toxicity induced by expanded CAG repeats in Huntington's disease.
Martí E
Brain Pathol; 2016 Nov; 26(6):779-786. PubMed ID: 27529325
[TBL] [Abstract][Full Text] [Related]
16. Proteostasis of Huntingtin in Health and Disease.
Koyuncu S; Fatima A; Gutierrez-Garcia R; Vilchez D
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753941
[TBL] [Abstract][Full Text] [Related]
17. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
18. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
[TBL] [Abstract][Full Text] [Related]
19. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
20. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
